Information Provided By:
Fly News Breaks for July 24, 2017
HCP
Jul 24, 2017 | 06:47 EDT
Goldman analyst Andrew Rosivach downgraded HCP to Neutral and trimmed its price target to $32 from $35 saying legacy issues related to "HCP 2.0" investments will continue to impact earnings negatively and expects shares to pause as the market digests and earnings rebase.